Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 234, Issue 1-2, Pages 63-70Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2011.02.006
Keywords
Natural antibody; TCR; Immunomodulation; EAE
Categories
Funding
- FAPESP [98/115195]
- Instituto de Salud Carlos III [FIS PI080102, CCG08-UCM/SAL-4215]
Ask authors/readers for more resources
The therapeutic potential of natural anti-T-cell receptor (TCR) antibodies is largely unknown. We investigated whether passive administration of C1-19, a novel natural anti-TCRV beta 8 monoclonal antibody, could interfere with the development of EAE. Treatment with C1-19 prevented myelin basic protein (MBP)-induced EAE in VIM-sufficient B10.PL but not in V beta 8-deficient SJL mice. Furthermore, C1-19 reduced disease severity when administrated shortly after disease onset. These protective effects of C1-19 correlated with a Th2 bias of the cytokine response, in the absence of T-cell deletion or anergy. Together, these findings indicate that natural anti-TCR antibodies could function as therapeutic tools in autoimmune inflammatory diseases. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available